Exclusive Summary

• UB667 is a preclinical, liver-targeted, long-acting GalNAc siRNA subcutaneous injection designed for the treatment of various hemophilia subtypes.
• Positioned as a potential Best-in-class therapy, it has demonstrated superior bleeding-control efficacy in animal models compared to the marketed competitor (Alnylam/Sanofi's Fitusiran).
• The asset is backed by a patent-protected GalNAc delivery platform and AI-assisted sequence design, providing a high technical barrier and clear IP for global development.
• It addresses the significant unmet clinical need of frequent dosing while offering high cost-effectiveness, well-positioned to penetrate the $15.8 billion global market.
• With PCC selected and animal PK completed, the derisked profile and flexible business models make it highly attractive for MNCs regarding license-out or co-development.

Asset Materials

Contact Us for Full Materials